Next Article in Journal
Structure of Lacticaseicin 30 and Its Engineered Variants Revealed an Interplay between the N-Terminal and C-Terminal Regions in the Activity against Gram-Negative Bacteria
Next Article in Special Issue
Protein Modification Employing Non-Canonical Amino Acids to Prepare SUMOylation Detecting Bioconjugates
Previous Article in Journal
Systematic Evaluation of Voriconazole Pharmacokinetic Models without Pharmacogenetic Information for Bayesian Forecasting in Critically Ill Patients
 
 
Review
Peer-Review Record

“Targeting Design” of Nanoparticles in Tumor Therapy

Pharmaceutics 2022, 14(9), 1919; https://doi.org/10.3390/pharmaceutics14091919
by Tingting Yang 1,†, Jingming Zhai 2,†, Dong Hu 1, Ruyue Yang 1, Guidan Wang 1, Yuanpei Li 1,* and Gaofeng Liang 1,*
Reviewer 1: Anonymous
Reviewer 2: Anonymous
Reviewer 3:
Reviewer 4: Anonymous
Pharmaceutics 2022, 14(9), 1919; https://doi.org/10.3390/pharmaceutics14091919
Submission received: 1 August 2022 / Revised: 1 September 2022 / Accepted: 6 September 2022 / Published: 11 September 2022

Round 1

Reviewer 1 Report

Please find the attached PDF for comments and suggestions.

Comments for author File: Comments.pdf

Author Response

请参阅附件

Author Response File: Author Response.pdf

Reviewer 2 Report

Comments

 

Comments for author File: Comments.pdf

Author Response

Please see the attachment

Author Response File: Author Response.pdf

Reviewer 3 Report

Please find the report pdf file attached.

Comments for author File: Comments.pdf

Author Response

Please see the attachment

Author Response File: Author Response.pdf

Reviewer 4 Report

The authors have written a good summary and informative review on nanoparticle design in Tumor Therapy. The topic is of interest, the article also showed the critical synthesis of the knowledge from the previous studies. The major context of the article not only included the findings from other reports but also provided complete discussion or suggestions that would be worthy for future research. Thus, the reviewer suggests that this article could be appropriate for this journal after minor revision.

1.       Although the authors mentioned that most targeted NPs delivery strategies are still in the pre-clinical trial stage, they did not discuss what major factors that prevent NPs delivery from the clinical applications. Because only the NP design or modification targeting to resolve those factors is really meaningful for tumor therapy in the clinic.

2.       Actually nanoparticles delivery strategy in cancer treatment in clinical trials has been reported, please discuss this part in this review with updated publications.

 

3.       There are many errors for citation in the text (lines 114, 148, 180, 229, 284, 578, 581, etc.). Please check and correct them.

Author Response

Please see the attachment

Author Response File: Author Response.pdf

Round 2

Reviewer 1 Report

Dear aiuthors,

Please correct the following.

 

Line 505: vβ3 and vβ3  integrin --> vβ3 and vβ5 integrin

Line 137 and many other lines: Error! Reference source not found. 

Reviewer 2 Report

Responses are satisfactory.

Back to TopTop